The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02735707




Registration number
NCT02735707
Ethics application status
Date submitted
11/12/2015
Date registered
13/04/2016
Date last updated
16/04/2020

Titles & IDs
Public title
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Scientific title
Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia
Secondary ID [1] 0 0
2015-002340-14
Secondary ID [2] 0 0
U1111-1189-1653
Universal Trial Number (UTN)
Trial acronym
REMAP-CAP
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Community-acquired Pneumonia, Influenza, COVID-19 0 0
Condition category
Condition code
Respiratory 0 0 0 0
Other respiratory disorders / diseases
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Fixed-duration Hydrocortisone
Treatment: Drugs - Shock-dependent hydrocortisone
Treatment: Drugs - Ceftriaxone
Treatment: Drugs - Moxifloxacin or Levofloxacin
Treatment: Drugs - Piperacillin-tazobactam
Treatment: Drugs - Ceftaroline
Treatment: Drugs - Amoxicillin-clavulanate
Treatment: Drugs - Macrolide administered for 3-5 days
Treatment: Drugs - Macrolide administered for up to 14 days
Treatment: Drugs - Five-days oseltamivir
Treatment: Drugs - Ten-days oseltamivir
Treatment: Drugs - Lopinavir/ritonavir
Treatment: Drugs - Hydroxychloroquine
Treatment: Drugs - Hydroxychloroquine + lopinavir/ritonavir
Treatment: Drugs - Interferon-ß1a
Treatment: Drugs - Anakinra
Treatment: Drugs - Fixed-duration higher dose Hydrocortisone
Treatment: Drugs - Tocilizumab
Treatment: Drugs - Sarilumab

Active Comparator: Corticosteroid Domain: fixed-duration Hydrocortisone - The patient will receive IV Hydrocortisone 50 mg every 6 hours for up to 7 days.

No Intervention: Corticosteroid Domain:No systemic corticosteroid (no placebo) - The patient will receive no systemic corticosteroid for the treatment of CAP or its direct complications, up until study day 28.

Active Comparator: Corticosteroid Domain: shock dependant Hydrocortisone - The patient will receive hydrocortisone (50mg IV every 6 hours) while the patient is in septic shock.

Active Comparator: Antibiotic Domain: Ceftriaxone + Macrolide - Ceftriaxone and site preferred macrolide will be administered for empiric antibiotic therapy

Active Comparator: Antibiotic Domain: Moxifloxacin or Levofloxacin - Moxifloxacin or levofloxacin will be administered for empiric antibiotic therapy

Active Comparator: Antibiotic Domain: Piperacillin-tazobactam + Macrolide - Piperacillin-tazobactam and site preferred macrolide will be administered for empiric antibiotic therapy

Active Comparator: Antibiotic Domain: Ceftaroline + Macrolide - Ceftaroline and site preferred macrolide will be administered for empiric antibiotic therapy

Active Comparator: Antibiotic Domain: Amoxicillin-clavulanate + Macrolide - Amoxicillin-clavunate and site preferred macrolide will be administered for empiric antibiotic therapy

Active Comparator: Macrolide Duration Domain: Standard course macrolide - The patient will receive macrolide therapy for 3-5 days. This arm is nested within the Antibiotic Domain.

Active Comparator: Macrolide Duration Domain: Extended course macrolide - The patient will receive macrolide therapy for up to 14 days. This arm is nested within the Antibiotic Domain.

No Intervention: No antiviral agent active against influenza (no placebo) - The patient will receive no antiviral agent active against influenza, including oseltamivir.

Active Comparator: Five-day course of Oseltamivir - The patient will receive a five-day course of oseltamivir.

Active Comparator: 10-day course of oseltamivir - The patient will receive a ten-day course of oseltamivir.

No Intervention: No antiviral for COVID-19 - The patient will receive no antiviral agent intended to be active against SARS-CoV-2 infection.

Active Comparator: Lopinavir/ritonavir for COVID-19 - Patients will receive lopinavir/ritonavir (kaletra) 400/100mg enterally every 12 hours intended to be active against SARS-CoV-2 infection.

Active Comparator: Hydroxychloroquine for COVID-19 - Patients will receive hydroxychloroquine intended to be active against SARS-CoV-2 infection.

Active Comparator: Hydroxychloroquine + lopinavir/ritonavir for COVID-19 - Patients will receive both hydroxychloroquine and lopinavir/ritonavir intended to be active against SARS-CoV-2 infection.

No Intervention: No immune modulation for COVID-19 - Patients will not receive any immune modulating therapy intended to be active against COVID-19.

Active Comparator: Interferon-ß1a for COVID-19 - Patients will receive Interferon-ß1a intended to be active against COVID-19.

Active Comparator: Anakinra (interleukin-1 receptor antagonist) for COVID-19 - Patients will receive anakinra intended to be active against COVID-19.

Active Comparator: Fixed-duration higher dose Hydrocortisone - The patient will receive IV Hydrocortisone 100mg every 6 hours for up to 7 days.

Active Comparator: Tocilizumab - Patients will receive Tocilizumab intended to be active against COVID-19

Active Comparator: Sarilumab - Patients will receive Sarilumab intended to be active against COVID-19


Treatment: Drugs: Fixed-duration Hydrocortisone
50mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

Treatment: Drugs: Shock-dependent hydrocortisone
Patient will receive 50mg IV hydrocortisone every 6 hours while the patient is in septic shock

Treatment: Drugs: Ceftriaxone
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Treatment: Drugs: Moxifloxacin or Levofloxacin
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Treatment: Drugs: Piperacillin-tazobactam
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Treatment: Drugs: Ceftaroline
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.
Ceftaroline is not available at commencement

Treatment: Drugs: Amoxicillin-clavulanate
The duration and dose of empiric antibiotics will be determined by the treating clinician and local guidelines or practice.

Treatment: Drugs: Macrolide administered for 3-5 days
Standard course of macrolide therapy, discontinued between study day 3 and the end of study day 5.
The dosing of and route of administration is not protocolised, the following guidance is provided:
Initial IV administration of a macrolide is strongly preferred
The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

Treatment: Drugs: Macrolide administered for up to 14 days
Extended course of macrolide therapy discontinued at the end of study day 14 or hospital discharge (whichever occurs first).
The dosing of and route of administration is not protocolised, the following guidance is provided:
Initial IV administration of a macrolide is strongly preferred
The preferred IV macrolide is azithromycin, but IV clarithromycin may be substituted.
The preferred enteral macrolide is azithromycin, but enteral clarithromycin or roxithromycin may be substituted.

Treatment: Drugs: Five-days oseltamivir
Oseltamivir administered enterally twice daily for 5 days or until hospital discharge (whichever occurs first)

Treatment: Drugs: Ten-days oseltamivir
Oseltamivir administered enterally twice daily for 10 days or until hospital discharge (whichever occurs first)

Treatment: Drugs: Lopinavir/ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.

Treatment: Drugs: Hydroxychloroquine
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).

Treatment: Drugs: Hydroxychloroquine + lopinavir/ritonavir
Lopinavir/ritonavir 400/100mg administered enterally, or 5ml 80/20mg per mL solution suspension via gastric tube, every 12 hours. Administered for a minimum of 5 days, including if discharged from ICU prior to end of study day 5. For patients discharged from ICU between study day 6 and study day 14, lopinavir/ritonavir is ceased at ICU discharge. Lopinavir/ritonavir is ceased at the end of study day 14 if the patient remains in ICU.
Loading dose of 800mg hydroxychloroquine administered enterally every 6 hours until 2 doses have been administered. Subsequently, 400mg hydroxychloroquine will be administered enterally every 12 hours for 12 doses or ICU discharge (whichever occurs first).

Treatment: Drugs: Interferon-ß1a
IFN-ß1a 10 µg will be administered as an intravenous bolus injection via a central or peripheral line. IFN-ß1a will be administered once daily for 6 days or until ICU discharge, whichever occurs first.

Treatment: Drugs: Anakinra
A loading dose of 300mg anakinra will be administered as a bolus via central or peripheral line. This is followed by maintenance doses of 100mg of anakinra administered very 6 hours.
In patients with renal impairment, anakinra will be administered on alternate days.

Treatment: Drugs: Fixed-duration higher dose Hydrocortisone
100mg of intravenous hydrocortisone will be administered every 6 hours for up to 7 days.

Treatment: Drugs: Tocilizumab
Tocilizumab will be administered as a single dose of 8mg/kg estimated or measured body weight, with a maximum total dose of 800mg.
Tocilizumab will be administered as an IV infusion via central or peripheral line over a one-hour period.

Treatment: Drugs: Sarilumab
Sarilumab will be administered as a single dose of 400mg, via IV infusion through peripheral or central line over a one-hour period.

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
All-cause mortality
Timepoint [1] 0 0
Day 90
Primary outcome [2] 0 0
Days alive and outside of ICU - Primary end-point for patients with suspected or proven COVID-19 pandemic infection
Timepoint [2] 0 0
Day 21
Secondary outcome [1] 0 0
ICU Mortality
Timepoint [1] 0 0
Day 90
Secondary outcome [2] 0 0
ICU length of stay
Timepoint [2] 0 0
Day 90
Secondary outcome [3] 0 0
Hospital length of stay
Timepoint [3] 0 0
Day 90
Secondary outcome [4] 0 0
Ventilator free days
Timepoint [4] 0 0
Day 28
Secondary outcome [5] 0 0
Organ failure free days
Timepoint [5] 0 0
Day 28
Secondary outcome [6] 0 0
All-cause mortality
Timepoint [6] 0 0
6 months
Secondary outcome [7] 0 0
Health-related Quality of life assessment - EQ5D-5L and WHODAS 2.0 (not completed in all regions)
Timepoint [7] 0 0
6 months
Secondary outcome [8] 0 0
Proportion of intubated patients who receive a tracheostomy
Timepoint [8] 0 0
Day 28
Secondary outcome [9] 0 0
Destination at time of hospital discharge - Characterised as home, rehabilitation hospital, nursing home or long-term care facility, or another acute hospital
Timepoint [9] 0 0
Free text Day 90
Secondary outcome [10] 0 0
Readmission to the index ICU during the index hospitalization
Timepoint [10] 0 0
Day 90
Secondary outcome [11] 0 0
World Health Organisation 8-point ordinal scale outcome
Timepoint [11] 0 0
Hospital discharge

Eligibility
Key inclusion criteria
REMAP-CAP PLATFORM INCLUSION CRITERIA:

1. Adult patient admitted to an ICU for severe CAP within 48 hours of hospital admission
with:

1. symptoms or signs or both that are consistent with lower respiratory tract
infection AND

2. Radiological evidence of new onset consolidation (in patients with pre-existing
radiological changes, evidence of new infiltrate)

2. Up to 48 hours after ICU admission, receiving organ support with one or more of:

1. Non-invasive or Invasive ventilatory support;

2. Receiving infusion of vasopressor or inotropes or both

PLATFORM EXCLUSION CRITERIA:

1. Healthcare-associated pneumonia:

1. Prior to this illness, is known to have been an inpatient in any healthcare
facility within the last 30 days

2. Resident of a nursing home or long term care facility

2. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more
of the patient, substitute decision maker or attending physician are not committed to
full active treatment

3. Previous participation in this REMAP within the last 90 days

REMAP-COVID PLATFORM INCLUSION CRITERIA

1. Adult patients (= 18 years) hospitalised with suspected or proven COVID-19 infection.
"Suspected COVID-19 infection" means the patient is clinically diagnosed based on symptoms
and/or exposure and for whom a microbiology test for COVID-19 has been/will be ordered, but
for whom the result is pending. "Proven COVID-19 infection" means the patient has a
confirmed positive result for COVID-19 based on microbiological testing.

ADDITIONAL PLATFORM INCLUSION CRITERIA FOR ICU-BASED REMAP-COVID DOMAINS

1. Admitted to an ICU with the following features suggestive of COVID-19-related
pneumonia:

1. symptoms or signs or both that are consistent with lower respiratory tract
infection AND

2. Radiological evidence of new onset consolidation (in patients with pre-existing
radiological changes, evidence of new infiltrate)

2. Up to 48 hours after ICU admission, receiving organ support with one or more of:

1. Non-invasive or Invasive ventilatory support;

2. Receiving infusion of vasopressor or inotropes or both

REMAP-COVID PLATFORM EXCLUSION CRITERIA

1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more
of the patient, substitute decision maker or attending physician are not committed to
full active treatment

2. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBLE CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more
information (www.remapcap.org).
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Factorial
Other design features
Phase
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,NT,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
St Vincent's Hospital Sydney - Sydney
Recruitment hospital [2] 0 0
Royal Prince Alfred Hospital - Sydney
Recruitment hospital [3] 0 0
Royal North Shore Hospital - Sydney
Recruitment hospital [4] 0 0
Nepean Hospital - Sydney
Recruitment hospital [5] 0 0
Wollongong Hospital - Sydney
Recruitment hospital [6] 0 0
Royal Darwin Hospital, - Darwin
Recruitment hospital [7] 0 0
Sunshine Coast University Hospital - Birtinya
Recruitment hospital [8] 0 0
Princess Alexandra Hospital - Brisbane
Recruitment hospital [9] 0 0
Logan Hospital - Brisbane
Recruitment hospital [10] 0 0
Toowoomba Hospital - Toowoomba
Recruitment hospital [11] 0 0
The Queen Elizabeth Hospital - Adelaide
Recruitment hospital [12] 0 0
Bendigo Hospital - Bendigo
Recruitment hospital [13] 0 0
University Hosptial Geelong - Geelong
Recruitment hospital [14] 0 0
The Alfred Hospital - Melbourne
Recruitment hospital [15] 0 0
Royal Melbourne Hospital - Melbourne
Recruitment hospital [16] 0 0
St Vincent's Hospital Melbourne - Melbourne
Recruitment hospital [17] 0 0
Royal Perth Hospital - Perth
Recruitment hospital [18] 0 0
Sir Charles Gairdner Hospital - Perth
Recruitment hospital [19] 0 0
St John of God Hospital Midland - Perth
Recruitment hospital [20] 0 0
Fiona Stanley Hospital - Perth
Recruitment hospital [21] 0 0
St John of God Hospital Murdoch - Perth
Recruitment postcode(s) [1] 0 0
2010 - Sydney
Recruitment postcode(s) [2] 0 0
2050 - Sydney
Recruitment postcode(s) [3] 0 0
2065 - Sydney
Recruitment postcode(s) [4] 0 0
2747 - Sydney
Recruitment postcode(s) [5] 0 0
8808 - Sydney
Recruitment postcode(s) [6] 0 0
0810 - Darwin
Recruitment postcode(s) [7] 0 0
4575 - Birtinya
Recruitment postcode(s) [8] 0 0
4102 - Brisbane
Recruitment postcode(s) [9] 0 0
4131 - Brisbane
Recruitment postcode(s) [10] 0 0
4350 - Toowoomba
Recruitment postcode(s) [11] 0 0
5011 - Adelaide
Recruitment postcode(s) [12] 0 0
3550 - Bendigo
Recruitment postcode(s) [13] 0 0
3220 - Geelong
Recruitment postcode(s) [14] 0 0
3004 - Melbourne
Recruitment postcode(s) [15] 0 0
3050 - Melbourne
Recruitment postcode(s) [16] 0 0
3065 - Melbourne
Recruitment postcode(s) [17] 0 0
6000 - Perth
Recruitment postcode(s) [18] 0 0
6009 - Perth
Recruitment postcode(s) [19] 0 0
6056 - Perth
Recruitment postcode(s) [20] 0 0
6150 - Perth
Recruitment outside Australia
Country [1] 0 0
Belgium
State/province [1] 0 0
Brugge
Country [2] 0 0
Belgium
State/province [2] 0 0
Charleroi
Country [3] 0 0
Belgium
State/province [3] 0 0
Edegem
Country [4] 0 0
Belgium
State/province [4] 0 0
Gent
Country [5] 0 0
Canada
State/province [5] 0 0
Hamilton
Country [6] 0 0
Canada
State/province [6] 0 0
Sherbrooke
Country [7] 0 0
Canada
State/province [7] 0 0
Toronto
Country [8] 0 0
Croatia
State/province [8] 0 0
Po┼żega
Country [9] 0 0
Croatia
State/province [9] 0 0
Zagreb
Country [10] 0 0
Germany
State/province [10] 0 0
Berlin
Country [11] 0 0
Germany
State/province [11] 0 0
Cologne
Country [12] 0 0
Germany
State/province [12] 0 0
Frankfurt
Country [13] 0 0
Germany
State/province [13] 0 0
Hamburg
Country [14] 0 0
Germany
State/province [14] 0 0
Hannover
Country [15] 0 0
Germany
State/province [15] 0 0
Jena
Country [16] 0 0
Germany
State/province [16] 0 0
Leipzig
Country [17] 0 0
Germany
State/province [17] 0 0
Tübingen
Country [18] 0 0
Germany
State/province [18] 0 0
Würzburg
Country [19] 0 0
Hungary
State/province [19] 0 0
Nyíregyháza
Country [20] 0 0
Hungary
State/province [20] 0 0
Veszprém
Country [21] 0 0
Hungary
State/province [21] 0 0
Ózd
Country [22] 0 0
Ireland
State/province [22] 0 0
Dublin
Country [23] 0 0
Ireland
State/province [23] 0 0
Galway
Country [24] 0 0
Netherlands
State/province [24] 0 0
Amersfoort
Country [25] 0 0
Netherlands
State/province [25] 0 0
Den Bosch
Country [26] 0 0
Netherlands
State/province [26] 0 0
Groningen
Country [27] 0 0
Netherlands
State/province [27] 0 0
Leiden
Country [28] 0 0
Netherlands
State/province [28] 0 0
Nijmegen
Country [29] 0 0
Netherlands
State/province [29] 0 0
Utrecht
Country [30] 0 0
New Zealand
State/province [30] 0 0
Auckland
Country [31] 0 0
New Zealand
State/province [31] 0 0
Christchurch
Country [32] 0 0
New Zealand
State/province [32] 0 0
Hamilton
Country [33] 0 0
New Zealand
State/province [33] 0 0
Rotorua
Country [34] 0 0
New Zealand
State/province [34] 0 0
Tauranga
Country [35] 0 0
New Zealand
State/province [35] 0 0
Wellington
Country [36] 0 0
New Zealand
State/province [36] 0 0
Whangarei
Country [37] 0 0
Portugal
State/province [37] 0 0
Abrantes
Country [38] 0 0
Portugal
State/province [38] 0 0
Lisboa
Country [39] 0 0
Romania
State/province [39] 0 0
Bucharest
Country [40] 0 0
Spain
State/province [40] 0 0
Barcelona
Country [41] 0 0
Spain
State/province [41] 0 0
Córdoba
Country [42] 0 0
United Kingdom
State/province [42] 0 0
Basingstoke
Country [43] 0 0
United Kingdom
State/province [43] 0 0
Bristol
Country [44] 0 0
United Kingdom
State/province [44] 0 0
Coventry
Country [45] 0 0
United Kingdom
State/province [45] 0 0
Darlington
Country [46] 0 0
United Kingdom
State/province [46] 0 0
Durham
Country [47] 0 0
United Kingdom
State/province [47] 0 0
Leeds
Country [48] 0 0
United Kingdom
State/province [48] 0 0
Maidstone
Country [49] 0 0
United Kingdom
State/province [49] 0 0
Middlesbrough
Country [50] 0 0
United Kingdom
State/province [50] 0 0
Milton Keynes
Country [51] 0 0
United Kingdom
State/province [51] 0 0
Northampton
Country [52] 0 0
United Kingdom
State/province [52] 0 0
Nottingham
Country [53] 0 0
United Kingdom
State/province [53] 0 0
Poole
Country [54] 0 0
United Kingdom
State/province [54] 0 0
Portsmouth
Country [55] 0 0
United Kingdom
State/province [55] 0 0
Reading
Country [56] 0 0
United Kingdom
State/province [56] 0 0
Stockton-on-Tees
Country [57] 0 0
United Kingdom
State/province [57] 0 0
Truro
Country [58] 0 0
United Kingdom
State/province [58] 0 0
Tunbridge Wells
Country [59] 0 0
United Kingdom
State/province [59] 0 0
York

Funding & Sponsors
Primary sponsor type
Other
Name
MJM Bonten
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Australian and New Zealand Intensive Care Research Centre
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Other
Name [2] 0 0
Medical Research Institute of New Zealand
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Other
Name [3] 0 0
Unity Health
Address [3] 0 0
Country [3] 0 0
Other collaborator category [4] 0 0
Other
Name [4] 0 0
Berry Consultants
Address [4] 0 0
Country [4] 0 0
Other collaborator category [5] 0 0
Other
Name [5] 0 0
Global Coalition for Adaptive Research
Address [5] 0 0
Country [5] 0 0
Other collaborator category [6] 0 0
Other
Name [6] 0 0
University of Pittsburgh Medical Center
Address [6] 0 0
Country [6] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
REMAP-CAP is a randomised, embedded, multifactorial, adaptive platform trial for
community-acquired pneumonia.

The purpose of this study is to evaluate the effect of a range of interventions to improve
outcome ofon patients admitted to intensive care with community-acquired pneumonia.

In addition, REMAP-CAP provides and adaptive research platform for evaluation of multiple
treatment modalities in the event of a respiratory pandemic resulting in critical illness.

REMAP-COVID is a sub-platform of REMAP-CAP that evaluates treatments specific to COVID-19.
Trial website
https://clinicaltrials.gov/show/NCT02735707
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Steve Webb, Prof
Address 0 0
Monash University, Study Chair REMAP-CAP Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Cameron Green
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
info@remapcap.org
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02735707